1stOncology™: Cancer Intelligence Service – Page 7194 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

NEXI, “Development of new immune anti-cancer drug” targeting ‘immune refractory factor’

On May 27, 2022 NEX-I reported the company has established 20 types of mouse models for refractory factors, and developed ‘NX-101,’ a candidate for an immunotherapy agent targeting solid tumors (Press release, NEX-I, MAY 27, 2022, View Source;mode=VIEW&num=18&category=&findType=&findWord=&sort1=&sort2=&page=3 [SID1234643435]). "We plan to complete non-clinical trials within next year and enter phase 1 clinical trials in the fourth quarter of next year."

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

NEX-I was founded in April last year by CEO Kyung-Wan Yoon, who served as Chief Scientific Officer (CSO) and Vice President at Genome & Company. Currently, about 15 people are working at Nexi, including Chief Operating Officer (COO) Vice President Son Jin-beop, and Chief Technology Officer (CTO) Professor Kim Tae-woo of Korea University, who are former DM Bio employees, and plans to add about 10 more people this year.

NexI was selected for the TIPS and Korea New Drug Development Foundation (KDDF) project last year, and attracted 4 billion won in pre-Series A. In particular, we will cooperate in the mid- to long-term with Daewoong Pharmaceutical, which participated as a strategic investor in Pre Series A, to develop pipelines such as non-small cell lung cancer (NSCLC) antibody candidate ‘NXI-101’ and metastatic melanoma antibody candidate ‘NXI-201’. We plan to continue research and development.

Nexi, developing an anti-cancer immunotherapy drug, attracts 4 billion won for Pre-A

On May 27, 2022 NEXI, is focusing on developing next-generation immunotherapy drugs, reported the company won 4 billion for Pre-A funding (Press release, NEX-I, MAY 27, 2022, View Source;mode=VIEW&num=17&category=&findType=&findWord=&sort1=&sort2=&page=3 [SID1234643434]). D.S.C.investment,Schmidt,Hana Ventures,Daewoong Pharmaceutical and others participated.

DSCSchmidt, a subsidiary of Investment, has8We helped select the TIPS project along with the monthly seed investment.,Participated in this follow-up investment as well..

Daewoong Pharmaceutical is a strategic investor and plans to seek cooperation measures such as joint research with NexI in the future..

Kim YohanDSCHead of Investment Biotech Division"Although there are differences depending on the cancer type, the response rate of existing immunotherapy drugs is20~30%There is an unmet medical need for this due to low severity..Nexi decided to make this investment because it fits this global development trend."He said.

Pre-AThe investment is for NexI’s next-generation immuno-anticancer drug pipeline.’NXI-101’class’NXI-201’It will be used for research and development of.

Kyung-wan Yoon, CEO of Nexi"With this investment, we will actively recruit excellent talent and accelerate research and development of anti-cancer drugs..We will do our best for overseas partnering starting next year."said.

The company said"Based on its independently built platform technology, Nexi has discovered a number of factors that induce anti-cancer immunotherapy drug refractoriness.,targeting thisFirst-in-classDeveloping new antibody drugs"as"We plan to administer it alone or in combination to cancer patients who do not respond to immunotherapy.,Through this, we will overcome the limitations of low response rates of existing immunotherapy drugs."He said.

Nexi announced earlier this monthNXI-101Established by being selected for national new drug development project through research8After about a month4Has been selected for 10 national projects.

Daewoong Pharmaceutical and Nexi MOU for joint development of immunotherapy drugs

On May 27, 2022 Daewoong Pharmaceutical reported on the 23rd that it signed a business agreement (MOU) with Nexi, a bio venture specializing in new drug development, for joint research and development of immunotherapy anti-cancer drugs and mid- to long-term cooperation (Press release, NEX-I, MAY 27, 2022, View Source;mode=VIEW&num=16&category=&findType=&findWord=&sort1=&sort2=&page=3 [SID1234643433]).

According to the announcement, NexI is developing new antibody drugs by targeting new immunotherapy refractory factors based on its proprietary platform technology. We plan to develop treatments alone or in combination with existing immunotherapy agents for cancer patients who cannot use immunotherapy agents or who do not respond to existing anticancer agents.

Through this agreement, Daewoong Pharmaceutical and NexI plan to jointly research and develop NexI’s pipeline, including the non-small cell lung cancer (NSCLC) antibody candidate ‘NXI-101’ and the metastatic melanoma antibody candidate ‘NXI-201’.

In particular, Daewoong Pharmaceutical plans to participate as a strategic investor (SI) in NexI’s Pre-A series investment, cooperate with NexI in overseas licensing out, and build various business models through mid- to long-term cooperation.

Seung-ho Jeon, CEO of Daewoong Pharmaceutical, said, "It is encouraging to be able to cooperate in the field of research and development with NexI, whose excellent technology has been proven through selection as a national project." He added, "We will continue to research innovative new drugs in the field of immunotherapy through open collaboration, which is Daewoong Pharmaceutical’s research and development strategy. "I will focus on this," he said.

Kyung-wan Yoon, CEO of Nexi, said, "We are pleased to have entered into a cooperative relationship with Daewoong Pharmaceutical," and added, "We will strive to achieve innovative results in the field of new immunotherapy drug development through close cooperation between the two companies in the future."

NexI’s ‘NXI-101’ selected as a national new drug development project

On May 27, 2022 NEX-I reported that the company selected NXI-101, a new antibody treatment for non-small cell lung cancer that targets immunotherapy-refractory factors (Press release, NEX-I, MAY 27, 2022, View Source;mode=VIEW&num=15&category=&findType=&findWord=&sort1=&sort2=&page=3 [SID1234643432]).

CEO Kyung-wan Yoon"NXI-101Not only does it improve the survival rate of patients who do not respond to existing immunotherapy treatments,,As an anticancer drug that guarantees the patient’s quality of life after treatment, it will bring a new paradigm to the cancer immunotherapy market."said.

The national new drug development project is a domestic pharmaceutical·To strengthen the global competitiveness of the bio industry and secure pharmaceutical sovereignty, which is an essential condition for public health, pharmaceutical companies and academia·kite·Based on bottle open innovation strategy,A pan-ministerial country that supports all stages of new drug developmentR&DStarting this year as a business10years2article2000Investing billions of won.

With the selection of this project, NexI plans to2yearsNXI-101You will receive support for the research costs necessary to derive the lead material.. NXI-101It targets immune evasion factors specifically secreted by cancer cells.First-in-classIt is a new antibody drug..Immune evasion factors are the cause of refractoriness to anticancer immunotherapy.,Controlling this can significantly improve the efficacy of anticancer immunotherapy..

The company said"New drugs under development are derived based on data from a number of immunotherapy-refractory animal models established in-house and from patients who are actually refractory to anti-cancer immunotherapy, so effective clinical efficacy can be expected."He said.

Meanwhile,Nexi this year4It is a new bio venture company established in February..Chief Scientific Officer of Genome & Company(CSO)·CEO Kyung-wan Yoon, who served as vice president,20Through more than a year of research on incurable cancer diseases, many anticancer drugs have been developed.·Professor Kim Tae-woo of Korea University College of Medicine, who has research achievements in immunotherapy, is the Chief Technology Officer.(CTO)I am in charge of.

Bolt Biotherapeutics to Present Ex Vivo Data Characterizing the Myeloid Cell Landscape in Solid Tumors at ASCO 2022

On May 27, 2022 Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, reported that it will be presenting a poster at the 2022 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, being held at McCormick Place in Chicago and virtually from June 3-7, 2022 (Press release, Bolt Biotherapeutics, MAY 27, 2022, View Source [SID1234618688]). The poster is titled "Characterization of tumor antigen expression and myeloid immune profiles to inform the development of immune-stimulating antibody conjugates (ISACs)."

"The data being presented at ASCO (Free ASCO Whitepaper) demonstrate that myeloid cells are consistently present in solid tumors. We believe this represents an attractive cellular target to address cancer more broadly. Myeloid cells are key cell types that serve as immunologic sentinels within the tumor microenvironment and can directly kill tumor cells or activate long-lasting cytotoxic T cells," said Edith A. Perez, M.D., Chief Medical Officer of Bolt Biotherapeutics. "Myeloid-targeted therapies, as single-agents or in combination with approved therapies, have the potential to benefit patients who may or may not have previously benefited from T cell-targeted approaches."

Bolt Biotherapeutics is currently developing a pipeline of myeloid-targeting therapies, including immune-stimulating antibody conjugates (ISACs) and BDC-3042 (a Dectin-2 agonistic antibody), designed to kill tumors through activation of myeloid cells and subsequent recruitment of T cells. Bolt researchers characterized the myeloid immune landscape of tumor microenvironments from five solid tumor types. The data demonstrate that myeloid cells are present in all tested tumor microenvironments, including those with low T cell infiltration. These findings support the potential for myeloid-directed therapies to activate the innate immune system as a bridge to adaptive immunity, including patient populations who have demonstrated resistance to T cell-mediated immune checkpoint blockade. The data also validate the tumor cell expression of tumor antigens HER2, CEA, and PD-L1, all of which are targets of Boltbody ISAC candidates.

The ASCO (Free ASCO Whitepaper) abstract and poster presentation can be found on the Bolt website under Events & Presentations. Details regarding the presentation are as follows.

Title: Characterization of tumor antigen expression and myeloid immune profiles to inform the development of immune stimulating antibody conjugates (ISACs)
Presented by: Jason Ptacek, Ph.D.
Poster Session: Developmental Therapeutics – Immunotherapy
Time: Sunday, June 5, 8:00 a.m. – 11:00 a.m. CDT
Abstract Number: 2557
Poster Number: 212